• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead

by June 8, 2026
written by June 8, 2026

Shares of Eli Lilly LLY climbed about 4% on Monday after the drugmaker unveiled encouraging new clinical data for its next-generation obesity treatment, retatrutide.

This has reinforced investor confidence in the company’s long-term position in the rapidly expanding weight-loss market.

The latest results were presented at the American Diabetes Association’s annual Scientific Sessions in New Orleans, where Lilly released full data from two late-stage retatrutide studies involving treatment-naive type 2 diabetes patients and individuals living with obesity.

The stock outperformed rival Novo Nordisk, whose US-listed shares declined during the session despite announcing that prescriptions for its oral weight-loss therapy Wegovy had surpassed 3 million since its January launch.

Wall Street appeared to favor Lilly’s expanding clinical pipeline over Novo’s commercial momentum, highlighting the growing competition between the two pharmaceutical giants that dominate the GLP-1 obesity market.

Retatrutide data strengthens Lilly’s obesity portfolio

Investors focused particularly on the performance of retatrutide’s 4 mg dose, which delivered approximately 19% weight loss in clinical testing.

According to analysts, the result is broadly comparable to the highest dose of Lilly’s blockbuster obesity therapy Zepbound. 

The lower dose also demonstrated favorable tolerability, with treatment discontinuation rates and instances of vomiting remaining relatively low, although side effects increased at higher doses.

“The 4mg dose efficacy data for retatrutide are compelling enough that first-line positioning cannot be dismissed,” Citi analysts wrote in a note. They added that the treatment could become “the next step for patients who have exhausted Lilly’s tirzepatide efficacy.”

Lilly also highlighted additional findings showing that retatrutide produced meaningful improvements in knee osteoarthritis pain and sleep apnea alongside substantial weight loss.

The company further presented data on its oral obesity treatment Foundayo, previously known as orforglipron.

Lilly said the pill was associated with significant weight loss in women across every stage of menopause based on analyses from its Phase 3 ATTAIN-1 and ATTAIN-2 clinical trials.

Novo Nordisk highlights commercial success

While Lilly showcased the breadth of its development pipeline, Novo Nordisk emphasized the commercial progress of its oral Wegovy therapy.

The company said US prescriptions for the treatment have exceeded 3 million since its launch in early January, describing it as one of the largest pharmaceutical launches in US history.

Goldman Sachs analyst Asad Haider acknowledged Novo’s early advantage after bringing oral Wegovy to market three months ahead of Lilly’s Foundayo.

“The Wegovy pill achieved instant popularity, making it ‘one of the best launches we’ve seen in pharmaceuticals — and it didn’t come at the expense of injectables,'” Haider said.

Even so, the analyst believes Lilly holds important long-term advantages.

“Our view remains that Lilly is going to continue to dominate the GLP-1 market across both existing therapies — oral and injectables — as well as next-generation,” Haider said.

He added: “We think it’s going to be hard for [Novo] to scale over the years to meet that international demand, whereas Lilly can.”

Analysts see Lilly extending its market leadership

Several analysts argued that Lilly’s broader obesity portfolio gives it a growing competitive edge.

J.P. Morgan analyst Chris Schott said, “LLY has the pieces in place to further raise the standard of care in the obesity space, and we see the company if anything further extending its leadership position in the $200 billion+ incretin/obesity market longer term.”

Citi Research analyst Geoff Meacham also maintained a positive outlook following the ADA conference.

“The company’s incretin portfolio is not built around singular blockbusters,” Meacham wrote.

In his view, orforglipron and retatrutide “carry development programs with enough indication breadth to make them category-defining franchises.”

Meacham also highlighted Lilly’s experimental obesity therapy eloralintide, saying the drug “adds a genuinely differentiated layer” to the company’s portfolio, with Phase 2 data suggesting potentially best-in-class efficacy and tolerability.

RBC Capital Markets analyst Trung Huynh echoed that view, saying the depth of Lilly’s obesity portfolio “highlighted its leadership growing rather than a narrowing gap with competitors”.

The post Eli Lilly stock rises as Retatrutide data boosts obesity drug lead appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why Nvidia stock is rebounding around 2% today
next post
Hong Kong deal positions Inno Holdings stock for a massive crash

related articles

Anthropic’s ANT closes at $97.17, up 17% on...

November 19, 2026

Evening digest: Anthropic makes historic debut, AMD falls...

November 19, 2026

Nvidia stock falls for sixth day as Anthropic...

November 19, 2026

Aswath Damodaran values Anthropic at $76 a share,...

November 19, 2026

Anthropic pops 34% to cross $2 trillion valuation...

November 19, 2026

Anthropic CEO Dario Amodei defends $900B AI spending...

November 19, 2026

Temu owner just cut its marketing bill: stock...

November 19, 2026

Best Trading Platforms to Buy Anthropic Stock (ANT)

November 19, 2026

AMD stock falls 7% as Hunterbrook alleges links...

November 19, 2026

Anthropic IPO: How much could ANT stock rise...

November 19, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Nasdaq opens 1.4% lower as chipmakers and AI infrastructure stocks extend loss

    November 5, 2026
  • GOP mail-in voting proposal could impact millions of Americans ahead of midterms

    September 3, 2026
  • Ex-Dem lawmaker beats Bernie-backed rival for shot at Utah’s most competitive House seat

    June 24, 2026
  • Kospi Index at a crossroads as Samsung, SK Hynix leverage bets reverse

    August 30, 2026
  • CrowdStrike stock is nearing its ATH: Top 3 reasons it may reverse soon

    July 14, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,663)
  • Stock (90)

Latest Posts

  • Micron stock faces fresh trouble after a 15% crash: is another selloff coming?

    October 20, 2026
  • Why Jim Cramer thinks Nvidia needs an Apple-style $500 billion stock buyback

    September 3, 2026
  • Dow sinks 480 points as AI selloff deepens, chip stocks extend losses

    July 17, 2026

Recent Posts

  • FIFA proposes a $20 billion spinoff of its commercial and events operations

    July 29, 2026
  • SK Hynix’s $26.5 billion Nasdaq debut explained: what investors should know

    July 10, 2026
  • Sentient’s Abhishek Saxena on AI reward hacking, model trust, and open weights

    November 3, 2026

Editor’s Pick

  • Trump’s Iran deal sparks GOP demands for vote as Congress remains in the dark

    June 16, 2026
  • Scottish Mortgage stock on edge ahead of SpaceX and Meta Platforms earnings

    October 20, 2026
  • Morningstar analyst sees Rolls-Royce stock jumping to 1,520p: will it?

    November 4, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock